• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

甲状腺结节的分子细胞病理学：方法学与检测性能综述

Molecular cytopathology for thyroid nodules: A review of methodology and test performance.

作者信息

Nishino Michiya

机构信息

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

出版信息

Cancer Cytopathol. 2016 Jan;124(1):14-27. doi: 10.1002/cncy.21612. Epub 2015 Sep 8.

DOI:10.1002/cncy.21612
PMID:26348024
Abstract

Advances in the molecular characterization of thyroid cancers have fueled the development of genetic and gene expression-based tests for thyroid fine-needle aspirations. Collectively, these tests are designed to improve the diagnostic certainty of thyroid cytology. This review summarizes the early published experience with the commercially available versions of these tests: the Afirma Gene Expression Classifier, ThyGenX (formerly miRInform)/ThyraMIR, and ThyroSeq. Key differences in testing approaches and issues regarding test performance and interpretation are also discussed.

摘要

甲状腺癌分子特征研究的进展推动了基于基因和基因表达的甲状腺细针穿刺检测技术的发展。总体而言，这些检测旨在提高甲状腺细胞学诊断的准确性。本综述总结了这些检测商业化版本（Afirma基因表达分类器、ThyGenX（原miRInform）/ThyraMIR和ThyroSeq）早期发表的经验。还讨论了检测方法的主要差异以及有关检测性能和解读的问题。

相似文献

1
Molecular cytopathology for thyroid nodules: A review of methodology and test performance.甲状腺结节的分子细胞病理学：方法学与检测性能综述
Cancer Cytopathol. 2016 Jan;124(1):14-27. doi: 10.1002/cncy.21612. Epub 2015 Sep 8.
2
Role of Ancillary Techniques in Thyroid Cytology Specimens.辅助技术在甲状腺细胞学标本中的作用
Acta Cytol. 2020;64(1-2):40-51. doi: 10.1159/000496502. Epub 2019 Apr 4.
3
Lessons from early clinical experience with the Afirma gene expression classifier.来自Afirma基因表达分类器早期临床经验的教训。
Cancer Cytopathol. 2014 Oct;122(10):715-9. doi: 10.1002/cncy.21472. Epub 2014 Aug 13.
4
An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.一项关于基因表达分类器（Afirma）在评估细胞学不确定的甲状腺结节中的独立研究。
J Clin Endocrinol Metab. 2014 Nov;99(11):4069-77. doi: 10.1210/jc.2013-3584. Epub 2014 Apr 29.
5
Clinical diagnostic gene expression thyroid testing.临床诊断性甲状腺基因表达检测
Otolaryngol Clin North Am. 2014 Aug;47(4):573-93. doi: 10.1016/j.otc.2014.04.009.
6
Benign call rate and molecular test result distribution of ThyroSeq v3.良性肿瘤的检出率和 ThyroSeq v3 的分子检测结果分布。
Cancer Cytopathol. 2019 Mar;127(3):161-168. doi: 10.1002/cncy.22088. Epub 2018 Dec 18.
7
Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.甲状腺细针穿刺活检结果不确定的甲状腺结节中超声特征与Afirma基因表达分类器结果之间的关系
AJR Am J Roentgenol. 2015 Oct;205(4):861-5. doi: 10.2214/AJR.14.13984.
8
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.甲状腺结节中 ThyroSeq v3 基因组分类器用于癌症诊断的分析性能。
Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18.
9
Molecular Testing of Thyroid Nodules: A Review of Current Available Tests for Fine-Needle Aspiration Specimens.甲状腺结节的分子检测：细针穿刺标本现有检测方法综述
Arch Pathol Lab Med. 2016 Dec;140(12):1338-1344. doi: 10.5858/arpa.2016-0100-RA. Epub 2016 Aug 24.
10
Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome.Afirma基因表达分类器结果对III/IV类甲状腺结节细针穿刺活检手术管理的影响及其与手术结果的相关性
Acta Cytol. 2016;60(3):205-10. doi: 10.1159/000446797. Epub 2016 Jun 25.

引用本文的文献

1
The Unappreciated Value of a Cheap, 'Good Enough' Method of Detecting Thyroid Cancer.一种廉价且“足够好”的甲状腺癌检测方法的未被重视的价值。
J Clin Med. 2024 Nov 30;13(23):7290. doi: 10.3390/jcm13237290.
2
BRAF Detection in FNAC Combined with Semi-Quantitative Tc-MIBI Technique and AI Model, an Economic and Efficient Predicting Tool for Malignancy in Thyroid Nodules.细针穿刺活检联合半定量锝-甲氧基异丁基异腈技术及人工智能模型检测BRAF，一种用于甲状腺结节恶性肿瘤的经济高效预测工具。
Diagnostics (Basel). 2024 Jun 30;14(13):1398. doi: 10.3390/diagnostics14131398.
3
How do and promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
和 启动子突变如何与甲状腺癌的 ATA 和 TNM 分期系统相互作用？
Front Endocrinol (Lausanne). 2023 Oct 4;14:1270796. doi: 10.3389/fendo.2023.1270796. eCollection 2023.
4
Diagnostic Performance of Afirma and Interpace Diagnostics Genetic Testing in Indeterminate Thyroid Nodules: A Single Center Study.Afirma和Interpace诊断基因检测在甲状腺结节诊断中的性能：一项单中心研究
Cancers (Basel). 2023 Mar 31;15(7):2098. doi: 10.3390/cancers15072098.
5
Follicular Growth Pattern Disease on Thyroid Fine-needle Aspiration Biopsy.甲状腺细针抽吸活检中的滤泡生长模式疾病。
Balkan Med J. 2022 Jul 22;39(4):230-238. doi: 10.4274/balkanmedj.galenos.2022.2022-5-17. Epub 2022 Jun 20.
6
Molecular Characterization of Thyroid Follicular Lesions in the Era of "Next-Generation" Techniques.在“下一代”技术时代甲状腺滤泡性病变的分子特征。
Front Endocrinol (Lausanne). 2022 May 12;13:834456. doi: 10.3389/fendo.2022.834456. eCollection 2022.
7
Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses.粗针活检可早期、精准地识别甲状腺大肿块。
Front Oncol. 2022 Apr 5;12:854755. doi: 10.3389/fonc.2022.854755. eCollection 2022.
8
Molecular Markers in the Diagnosis of Thyroid Cancer in Indeterminate Thyroid Nodules.不确定甲状腺结节中甲状腺癌诊断的分子标志物
Indian J Surg Oncol. 2022 Mar;13(1):11-16. doi: 10.1007/s13193-020-01112-8. Epub 2020 Jun 6.
9
Long-term Follow-up of Cytologically Indeterminate Thyroid Nodules Found Benign on Molecular Testing: A Validation Study.分子检测显示为良性的细胞学检查结果不确定的甲状腺结节的长期随访：一项验证研究
OTO Open. 2022 Mar 18;6(1):2473974X221083542. doi: 10.1177/2473974X221083542. eCollection 2022 Jan-Mar.
10
Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study.超声与分子检测联合在贝塞斯达四类甲状腺结节恶性风险评估中的应用：单中心前瞻性研究结果。
J Endocrinol Invest. 2021 Dec;44(12):2635-2643. doi: 10.1007/s40618-021-01571-y. Epub 2021 Apr 16.